Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CNCE&src=ctag” target=”_blank”gt;$CNCElt;/agt; lt;a href=”https://twitter.com/hashtag/AAD2019?src=hash” target=”_blank”gt;#AAD2019lt;/agt;–Concert
Pharmaceuticals, Inc.
(NASDAQ: CNCE) today announced that interim
clinical data from its CTP-543 Phase 2 trial in alopecia areata has been
selected for an oral presentation at the Late-Breaking Research Program
during the American Academy of Dermatology (AAD) Annual Meeting being
held March 1 – 5, 2019 in Washington, D.C.

The details of the presentation are as follows:

  • Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase
    2 Trial in Alopecia Areata
  • Date and Time: Saturday, March 2, 2019, 1:00 – 4:00 p.m.
  • Session: S034: Late-Breaking Research: Clinical Trials
  • Room: Ballroom A
  • Abstract Number: 11291

About CTP-543

CTP-543 was discovered by applying Concert’s deuterium chemistry
technology to modify ruxolitinib, a drug which inhibits Janus kinases 1
and 2 (JAK1 and JAK2) and is commercially available under the name
Jakafi® in the United States for the treatment of certain blood
disorders. Deuterium modification of ruxolitinib was found to alter its
human pharmacokinetics in ways which may enhance its use as a treatment
for alopecia areata. The U.S. Food and Drug Administration (FDA) has
granted Fast Track designation for CTP-543.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or
complete loss of hair on the scalp and body that may affect up to
650,000 Americans at any given time1. The scalp is the most
commonly affected area, but any hair-bearing site can be affected alone
or together with the scalp. Onset of the disease can occur throughout
life with the majority of patients initially having symptoms by age 40.
It is believed to equally affect both women and men. Alopecia areata can
be associated with serious psychological consequences, including anxiety
and depression. There are currently no drugs approved by the FDA for the
treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in
September 2017 on alopecia areata, the FDA summarized the input shared
by patients and patient representatives in a Voice
of the Patient
report. Additional information on the PFDDI is
available online.

About Concert

Concert
Pharmaceuticals
is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform®
(deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy.
Concert’s pipeline of
innovative medicines targets autoimmune diseases and central nervous
systems (CNS) disorders. For more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations,
plans and prospects, including statements about our expectations for
clinical development of CTP-543, and other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would,” and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: the uncertainties inherent in the
initiation of future clinical trials, whether preliminary results from a
clinical trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory approvals,
availability of funding sufficient for our foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the “Risk Factors” section of our most recent
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission and in other filings that we make with the Securities and
Exchange Commission. In addition, any forward-looking statements
included in this press release represent our views only as of the date
of this release and should not be relied upon as representing our views
as of any subsequent date. We specifically disclaim any obligation to
update any forward-looking statements included in this press release.

1 Fricke M. Epidemiology and Burden of alopecia areata: a
systemic review. Clinical, Cosmetic and Investigational Dermatology.
2015; Vol 8. 397-403.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Jakafi® is a registered trademark of Incyte Corporation.

Contacts

Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
(781)
674-5284
[email protected]

Kathryn
Morris (media)
The Yates Network
(914) 204-6412
[email protected]

error: Content is protected !!